Compugen Expands and Strengthens Business Development Team
23 Febrero 2015 - 6:04AM
Business Wire
Felix Karim, PhD, joins Company as Vice
President Corporate & Business Development
Compugen Ltd. (NASDAQ: CGEN) today announced the appointment of
Dr. Felix Karim as Vice President Corporate & Business
Development, effective March 2, 2015. Dr. Karim, who will be based
at Compugen’s South San Francisco facilities, will report to Dr.
Anat Cohen-Dayag, Compugen’s President and Chief Executive Officer,
and will have direct responsibility for the Company’s business
development strategy and its execution.
Dr. Cohen-Dayag, President and CEO of Compugen, stated, “We are
very pleased to welcome Felix to Compugen’s senior management team.
Felix brings to Compugen substantial experience and accomplishments
in a range of biopharma companies, from start-ups to leading public
companies, initially as a senior scientist and project leader, and
later as an executive with broad responsibilities in both R&D
and business development. We are excited to have the benefit of his
experience and capabilities as we evaluate a number of potential
collaboration options to maximize the value of our attractive early
stage target pipeline and our unique, broadly applicable predictive
discovery capabilities.”
Dr. Karim has significant experience in the biopharmaceutical
industry and has held various executive roles in business
development and R&D management. His most recent position prior
to joining Compugen was Head of External R&D (licensing) for
the San Francisco region at Amgen. Before Amgen, Dr. Karim was Vice
President of Business Development at KAI Pharmaceuticals, where he
led business development and transaction activities, including the
sale of KAI Pharmaceuticals to Amgen. Dr. Karim has also held
various positions at Exelixis and Celera Genomics, leading
multidisciplinary teams across a broad range of activities in
R&D and program development, and has played an integral role in
business development efforts that resulted in significant pharma
partnerships. Dr. Karim holds a bachelor’s degree in biochemistry
from the University of California, Berkeley, and a PhD from the
Department of Human Genetics at the University of Utah Medical
School.
About Compugen
Compugen is a leading drug discovery company focused on
monoclonal antibodies and therapeutic proteins to address important
unmet needs in the fields of oncology and immunology. The
Company utilizes a broad and continuously growing integrated
infrastructure of proprietary scientific understandings and
predictive platforms, algorithms, machine learning systems and
other computational biology capabilities for the in
silico (by computer) prediction and selection of novel drug
target candidates, which are then advanced in its Pipeline Program.
The discovery and development of monoclonal antibody therapeutic
candidates against selected Compugen-discovered novel target
candidates is performed by Compugen’s wholly-owned U.S. subsidiary
located in South San Francisco. The Company's business model
includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery
agreements, in both cases providing Compugen with potential
milestone payments and royalties on product sales or other forms of
revenue sharing. For additional information, please visit
Compugen's corporate website at http://www.cgen.com/.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as “will,” “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future
events and include statements related to potential collaboration
options to maximize the value of Compugen’s attractive early stage
target pipeline and its unique, broadly applicable predictive
discovery capabilities. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
inability to reach mutually agreeable terms and conditions with
respect to potential new collaborations; the impact of competitive
products and technological changes; risks relating to the
development of new products; and the ability to implement
technological improvements.
These and other factors are discussed in the "Risk Factors"
section of Compugen’s most recent Annual Report on Form 20-F as
filed with the Securities and Exchange Commission as well as other
documents that may be subsequently filed by Compugen from time to
time with the Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen Ltd.Tsipi Haitovsky, +972-52-598-9892Global Media
Liaisontsipih@cgen.com
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024